About
About Harbin Gloria Pharmaceuticals Co., Ltd
HARBIN GLORIA PHARMACEUTICALS Co., LTD, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China and internationally. The company offers cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamin supplements, electrolyte drugs, hypoglycemic drugs, analgesics, digestive system and metabolic drugs, anti-infective drugs, and anti-tumor drugs. It also provides deer antler polypeptide injections, Annao pills and tablets, potassium chloride sustained-release tablets, sodium creatine phosphate for injection, ginkgo biloba extract injections, vitamins (B12), fluorouracil for injection, bleomycin hydrochloride for injection, and other injectable products, as well as pravastatin sodium tablets, olmesartan medoxomil amlodipine tablets, and edoxaban tosylate tablets. In addition, the company engages in pharmaceutical promotion; project investment; investment services; trade import and export; wholesale and retail; and technology promotion and application services. Harbin Gloria Pharmaceuticals Co., Ltd was founded in 2000 and is headquartered in Harbin, the People's Republic of China.
Visit company website
5 years, 5 months ago
Harbin Gloria Pharmaceuticals Co., Ltd is currently in a long term downtrend where the price is trading 10.9% below its 200 day moving average.
From a valuation standpoint, the stock is 81.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.8.
Harbin Gloria Pharmaceuticals Co., Ltd's total revenue sank by 34.9% to $809M since the same quarter in the previous year.
Its net income has dropped by 114.5% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 106.3% to $-17M since the same quarter in the previous year.
Based on the above factors, Harbin Gloria Pharmaceuticals Co., Ltd gets an overall score of 1/5.